The Usefulness of a Novel Screening Kit for Colorectal Cancer Using the Immunochromatographic Fecal Tumor M2 Pyruvate Kinase Test

Overview

Journal Gut Liver

Specialty Gastroenterology

Date 2014 Dec 5

PMID 25473070

Citations 8

Authors

Yong Cheol Kim

Jeong Ho Kim

Dae Young Cheung

Tae Ho Kim

Eun Jung Jun

Jung-Whan Oh

Chang Whan Kim

Woo Chul Chung

Byung-Wook Kim

Sung Soo Kim

Jin Il Kim

Soo-Heon Park

Jae Kwang Kim

Affiliations

Soon will be listed here.

Abstract

Background/aims: M2 pyruvate kinase (M2-PK) is an enzyme that is produced in undifferentiated and proliferating tissues. This study aims to evaluate the usefulness of the immunochromatographic M2 pyruvate kinase (iM2-PK) for the screening of colorectal cancer (CRC) and premalignant lesions.

Methods: Healthy volunteers and patients with colorectal neoplasia were enrolled in six academic hospitals in the capital province of Korea. The iM2-PK value was compared with the immunochromatographic fecal occult blood test (iFOBT) and fecal tumor M2-PK enzyme-linked immunosorbent assay (ELISA).

Results: A total of 323 subjects were enrolled. The sensitivity of iM2-PK for CRC was 92.8%, which was superior to iFOBT (47.5%, p<0.0001). For adenomatous lesions, the sensitivity of iM2-PK was 69.4%, which was also superior to iFOBT (12.1%, p<0.001). Compared with M2-PK ELISA, iM2-PK exhibited significantly enhanced sensitivity for CRC (97.5% vs 80.0%, p=0.0289). The sensitivity of iM2-PK was higher in advanced stages of CRC compared with cancers confined to the mucosa and submucosa (p<0.05). However, lymph node metastasis had no influence on the sensitivity of iM2-PK.

Conclusions: The iM2-PK exhibited increased sensitivity for identifying CRC and adenomatous lesions compared with iFOBT. Given its rapid results and convenience, CRC screening using iM2-PK is promising.

Citing Articles

The Importance of Evaluating Serum Levels of Tumor Markers M2-PK and Inhibin A in Patients Undergoing Colonoscopy.

Khosravi M, Anoushirvani A, Kheiri Z, Rahbari A, Jadidi A Technol Cancer Res Treat. 2023; 22:15330338231194492.

PMID: 37574835 PMC: 10429987. DOI: 10.1177/15330338231194492.

Comparison of faecal protein biomarkers' diagnostic accuracy for colorectal advanced neoplasms: a systematic review and meta-analysis.

Nasir Kansestani A, Zare M, Tong Q, Zhang J Sci Rep. 2022; 12(1):2623.

PMID: 35173276 PMC: 8850428. DOI: 10.1038/s41598-022-06689-4.

Identifying Novel Biomarkers Ready for Evaluation in Low-Prevalence Populations for the Early Detection of Lower Gastrointestinal Cancers: A Systematic Review and Meta-Analysis.

Druce P, Calanzani N, Snudden C, Milley K, Boscott R, Behiyat D Adv Ther. 2021; 38(6):3032-3065.

PMID: 33907946 PMC: 8078393. DOI: 10.1007/s12325-021-01645-6.

The Antidiabetic and Antinephritic Activities of via Modulation of Nrf2-Mediated Oxidative Stress in the db/db Mouse.

Jiang X, Teng S, Wang X, Li S, Zhang Y, Wang D Oxid Med Cell Longev. 2018; 2018:7453865.

PMID: 30186548 PMC: 6087590. DOI: 10.1155/2018/7453865.

Evaluation of Fecal M2PK as a Diagnostic Marker in Colorectal Cancer.

Dabbous H, Mohamed Y, El-Folly R, El-Talkawy M, Seddik H, Johar D J Gastrointest Cancer. 2018; 50(3):442-450.

PMID: 29626277 DOI: 10.1007/s12029-018-0088-1.

References

Tonus C, Neupert G, Sellinger M . Colorectal cancer screening by non-invasive metabolic biomarker fecal tumor M2-PK. World J Gastroenterol. 2006; 12(43):7007-11. PMC: 4087345. DOI: 10.3748/wjg.v12.i43.7007. View

Jung K, Won Y, Kong H, Oh C, Seo H, Lee J . Cancer statistics in Korea: incidence, mortality, survival and prevalence in 2010. Cancer Res Treat. 2013; 45(1):1-14. PMC: 3629358. DOI: 10.4143/crt.2013.45.1.1. View

Haug U, Rothenbacher D, Wente M, Seiler C, Stegmaier C, Brenner H . Tumour M2-PK as a stool marker for colorectal cancer: comparative analysis in a large sample of unselected older adults vs colorectal cancer patients. Br J Cancer. 2007; 96(9):1329-34. PMC: 2360192. DOI: 10.1038/sj.bjc.6603712. View

Koss K, Maxton D, Jankowski J . Faecal dimeric M2 pyruvate kinase in colorectal cancer and polyps correlates with tumour staging and surgical intervention. Colorectal Dis. 2007; 10(3):244-8. DOI: 10.1111/j.1463-1318.2007.01334.x. View

Hewitson P, Glasziou P, Watson E, Towler B, Irwig L . Cochrane systematic review of colorectal cancer screening using the fecal occult blood test (hemoccult): an update. Am J Gastroenterol. 2008; 103(6):1541-9. DOI: 10.1111/j.1572-0241.2008.01875.x. View

Lynch N, McHutchison J, Young G, Deacon M, St John D, Barraclough D . Gastrointestinal blood loss from a new buffered aspirin (Ostoprin): measurement by radiochromium and Hemoquant techniques. Aust N Z J Med. 1989; 19(2):89-96. DOI: 10.1111/j.1445-5994.1989.tb00210.x. View

Christofk H, Vander Heiden M, Harris M, Ramanathan A, Gerszten R, Wei R . The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth. Nature. 2008; 452(7184):230-3. DOI: 10.1038/nature06734. View

Hardt P, Ngoumou B, Rupp J, Kloer H . Tumor M2-pyruvate kinase: a promising tumor marker in the diagnosis of gastro-intestinal cancer. Anticancer Res. 2001; 20(6D):4965-8. View

Zhu M, Xu X, Nie F, Tong J, Xiao S, Ran Z . Comparison of immunochemical and guaiac-based fecal occult blood test in screening and surveillance for advanced colorectal neoplasms: a meta-analysis. J Dig Dis. 2010; 11(3):148-60. DOI: 10.1111/j.1751-2980.2010.00430.x. View

10.

Abdullah M, Rani A, Simadibrata M, Fauzi A, Syam A . The value of fecal tumor M2 pyruvate kinase as a diagnostic tool for colorectal cancer screening. Acta Med Indones. 2012; 44(2):94-9. View

11.

Allison J, Fraser C, Halloran S, Young G . Population screening for colorectal cancer means getting FIT: the past, present, and future of colorectal cancer screening using the fecal immunochemical test for hemoglobin (FIT). Gut Liver. 2014; 8(2):117-30. PMC: 3964261. DOI: 10.5009/gnl.2014.8.2.117. View

12.

Tonus C, Sellinger M, Koss K, Neupert G . Faecal pyruvate kinase isoenzyme type M2 for colorectal cancer screening: a meta-analysis. World J Gastroenterol. 2012; 18(30):4004-11. PMC: 3419997. DOI: 10.3748/wjg.v18.i30.4004. View

13.

Shastri Y, Loitsch S, Hoepffner N, Povse N, Hanisch E, Rosch W . Comparison of an established simple office-based immunological FOBT with fecal tumor pyruvate kinase type M2 (M2-PK) for colorectal cancer screening: prospective multicenter study. Am J Gastroenterol. 2008; 103(6):1496-504. DOI: 10.1111/j.1572-0241.2008.01824.x. View

14.

Duffy M, van Rossum L, van Turenhout S, Malminiemi O, Sturgeon C, Lamerz R . Use of faecal markers in screening for colorectal neoplasia: a European group on tumor markers position paper. Int J Cancer. 2010; 128(1):3-11. DOI: 10.1002/ijc.25654. View

15.

Whitlock E, Lin J, Liles E, Beil T, Fu R . Screening for colorectal cancer: a targeted, updated systematic review for the U.S. Preventive Services Task Force. Ann Intern Med. 2008; 149(9):638-58. DOI: 10.7326/0003-4819-149-9-200811040-00245. View

16.

Ahlquist D, Skoletsky J, Boynton K, Harrington J, Mahoney D, Pierceall W . Colorectal cancer screening by detection of altered human DNA in stool: feasibility of a multitarget assay panel. Gastroenterology. 2000; 119(5):1219-27. DOI: 10.1053/gast.2000.19580. View

17.

Mulder S, van Leerdam M, van Vuuren A, Francke J, van Toorenenbergen A, Kuipers E . Tumor pyruvate kinase isoenzyme type M2 and immunochemical fecal occult blood test: performance in screening for colorectal cancer. Eur J Gastroenterol Hepatol. 2007; 19(10):878-82. DOI: 10.1097/MEG.0b013e3282cfa49c. View

18.

Christofk H, Vander Heiden M, Wu N, Asara J, Cantley L . Pyruvate kinase M2 is a phosphotyrosine-binding protein. Nature. 2008; 452(7184):181-6. DOI: 10.1038/nature06667. View

19.

Hardt P, Mazurek S, Toepler M, Schlierbach P, Bretzel R, Eigenbrodt E . Faecal tumour M2 pyruvate kinase: a new, sensitive screening tool for colorectal cancer. Br J Cancer. 2004; 91(5):980-4. PMC: 2409989. DOI: 10.1038/sj.bjc.6602033. View

20.

Haug U, Hundt S, Brenner H . Sensitivity and specificity of faecal tumour M2 pyruvate kinase for detection of colorectal adenomas in a large screening study. Br J Cancer. 2008; 99(1):133-5. PMC: 2453015. DOI: 10.1038/sj.bjc.6604427. View